The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna ...

US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

A contract for the running of a youth alcohol and other drug rehabilitation centre has been awarded to a Far North ...

Cobenfy is the first FDA-approved antipsychotic that targets cholinergic receptors instead of dopamine receptors.

Zevra Therapeutics' drug, Miplyffa, for treating a rare and fatal genetic disorder will have a wholesale acquisition cost ...

EPD will also have a new "deflection" program. It's a system in which drug addicts can be taken to a treatment center instead of jail. Chief Skinner believes the new program will increase interactions ...

The funding will be directed towards rehabilitation and community reintegration efforts, with $15.9 million allocated for capital works and $4.1 million for operational expenses. Corrections Minister ...

Hundreds of blood cancer patients will be able to access a ‘game changer’ drug which will allow them ... cent of patients’ cancers responded to treatment with zanubrutinib, according to ...

Giving women at risk of premature birth a simple magnesium sulfate infusion (or 'drip') can prevent their babies from ...

In the world of biotechnology, few stories resonate as strongly as that of Pasithea Therapeutics Corp. (NASDAQ: KTTA). On Thursday, the stock saw an impressive surge of +80.31%, reaching $6.90 during ...